Clinical Trial Update: FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 trial of FOLFIRINOX in metastatic high-grade gastroenteropancreatic neuroendocrine carcinomas was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastro-enteropancreatic Neuroendocrine Tumor
• Islet Cell Carcinoma
• Neuroendocrine Carcinomas of Pancreas
• Pancreatic Cancer

Drugs mentioned

• FOLFIRINOX

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-12-11